Source:http://linkedlifedata.com/resource/pubmed/id/11906533
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2002-3-21
|
| pubmed:abstractText |
Using a combination of the selective opioid receptor-like1 (ORL1) receptor agonist, Ro 64-6198, and orphanin FQ/nociceptin (OFQ/N) peptide knockout (KO) mice, the influence of OFQ/N on cognition has been studied in the rodent. In wild type, C57BL/6J mice, Ro 64-6198 (0.3-1 mg/kg i.p.) impaired the acquisition of spatial learning in the Morris water maze, although a mild neurological impairment was evident which complicated precise interpretation. In Lister hooded rats, Ro 64-6198 (6 mg/kg i.p.) produced delay dependent impairments in rats performing either a delayed matching or a delayed nonmatching to position task with only a modest (< 20%) effect on omissions - an effect consistent with a short-term memory impairment. Electrophysiological studies demonstrated an inhibitory effect of OFQ/N on LTP recorded from the CA1 region of wild type mice, but not in ORL1 receptor knockout mice. In contrast to the ORL1 agonist, mice deficient in the OFQ/N peptide showed some evidence of improved spatial learning, fear conditioning and passive avoidance retention. However, CA1 LTP was similar between OFQ/N peptide KO mice and wild type controls. Subsequent receptor radioautography studies demonstrated the presence of ORL1 receptors within various regions of the medial temporal lobe system: i.e. CA1, dentate gyrus molecular layer, subiculum, perirhinal cortex. Taken together, these results suggest a bi-directional effect of OFQ/N containing systems on aspects of cognitive behaviour, particularly those elements associated with hippocampal function. This is consistent with a likely modulatory role of OFQ/N on hippocampal and associated cortical circuitry.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Anxiety Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Opioid Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/Ro 64-6198,
http://linkedlifedata.com/resource/pubmed/chemical/Spiro Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/nociceptin,
http://linkedlifedata.com/resource/pubmed/chemical/nociceptin receptor
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0953-816X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
911-22
|
| pubmed:dateRevised |
2005-12-20
|
| pubmed:meshHeading |
pubmed-meshheading:11906533-Animals,
pubmed-meshheading:11906533-Anti-Anxiety Agents,
pubmed-meshheading:11906533-Avoidance Learning,
pubmed-meshheading:11906533-Cognition,
pubmed-meshheading:11906533-Conditioning (Psychology),
pubmed-meshheading:11906533-Dose-Response Relationship, Drug,
pubmed-meshheading:11906533-Excitatory Postsynaptic Potentials,
pubmed-meshheading:11906533-Hippocampus,
pubmed-meshheading:11906533-Imidazoles,
pubmed-meshheading:11906533-Long-Term Potentiation,
pubmed-meshheading:11906533-Male,
pubmed-meshheading:11906533-Maze Learning,
pubmed-meshheading:11906533-Memory,
pubmed-meshheading:11906533-Mice,
pubmed-meshheading:11906533-Mice, Inbred C57BL,
pubmed-meshheading:11906533-Mice, Knockout,
pubmed-meshheading:11906533-Neurons,
pubmed-meshheading:11906533-Opioid Peptides,
pubmed-meshheading:11906533-Radioligand Assay,
pubmed-meshheading:11906533-Rats,
pubmed-meshheading:11906533-Rats, Inbred Strains,
pubmed-meshheading:11906533-Receptors, Opioid,
pubmed-meshheading:11906533-Space Perception,
pubmed-meshheading:11906533-Spiro Compounds
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory.
|
| pubmed:affiliation |
PRBN, F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland.
|
| pubmed:publicationType |
Journal Article
|